The authors of this study1 should be commended on the important and complex undertaking of identifying multiple antigens for chimeric antigen receptor (CAR) T-cell therapy, which is one of several key limitations to the field. There are 2 levels of antigenic heterogeneity at play that require consideration—intrapatient variability, in which the existence of antigen-negative tumor cells may result in eventual recurrence, and interpatient variability, in which different expression patterns across all patients make identification of a single or "universal" therapeutic for treatment difficult, if not impossible. The authors state that by targeting 3 antigens: human epidermal growth factor receptor 2 (HER2), interleukin-13 receptor alpha 2 (IL13Rα2), and ephrin-A2 (EphA2) using a trivalent UCAR, they can "overcome intrapatient and interpatient variability" and that "trivalent T cells were able to approach killing in 100% of tumor cells in nearly all patients modeled." As investigators working in the field of immuno-oncology, we very much wish this to be the case; however, these conclusions are not supported by the data presented in the manuscript.
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00306932607174,00302841026182,alsfakia@gmail.com
Αναζήτηση αυτού του ιστολογίου
Πληροφορίες
Ετικέτες
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: Available online 25 July 2018 Source: Journal of Photochemistry and Photobiology B: Biology Author(s): Marco Ballestr...
-
Editorial AJR Reviewers: Heartfelt Thanks From the Editors and Staff Thomas H. Berquist 1 Share + Affiliation: Citation: American Journal...
-
https://www.youtube.com/watch?v=DFOhpBjLqN4&t=1s , Η ΘΕΡΑΠΕΙΑ ΓΙΑ ΟΛΕΣ ΤΙΣ ΑΣΘΕΝΕΙΕΣ 1 Περιεχόμενα Σύντομο βιογραφικό Πρόλογος μεταφραστ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.